Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GSK3B | P49841 | 10/20 | 0.73 |
| ▸ | CDK2 | P24941 | 9/20 | 0.70 |
| ▸ | CCNA2 | P20248 | 1/20 | 0.62 |
| ▸ | CCNA1 | P78396 | 1/20 | 0.62 |
| ▸ | CCNE1 | P24864 | 1/20 | 0.45 |
| ▸ | MAPK14 | Q16539 | 2/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13146723 | 0.94 | GSK3B (0.70) | GSK3BCDK2CCNA2CCNA1CCNE1 | |
| SCHEMBL12953835 | 0.87 | GSK3B (0.73) | GSK3BCDK2CCNA2CCNA1CCNE1 | |
| SCHEMBL14043202 | 0.86 | GSK3B (0.72) | GSK3BCDK2CCNA2CCNA1CCNE1 | |
| SCHEMBL12953281 | 0.86 | GSK3B (0.72) | GSK3BCDK2CCNA2CCNA1CCNE1 | |
| SCHEMBL12953680 | 0.85 | GSK3B (0.71) | GSK3BCDK2CCNA2CCNA1CCNE1 | |
| SCHEMBL13305408 | 0.85 | GSK3B (0.74) | GSK3BCDK2CCNA2CCNA1CCNE1 | |
| SCHEMBL14418674 | 0.85 | GSK3B (0.53) | GSK3BCDK2CCNA2CCNA1CCNE1 | |
| SCHEMBL12953538 | 0.85 | GSK3B (0.64) | GSK3BCDK2CCNA2CCNA1CCNE1 | |
| SCHEMBL13118479 | 0.84 | GSK3B (1.00) | GSK3BCDK2CCNA2CCNA1CCNE1 | |
| SCHEMBL12953525 | 0.84 | GSK3B (0.61) | GSK3BCDK2CCNA2CCNA1CCNE1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8580782-B2 | Substituted pyrazolo[1,5-a]pyrimidines as cyclin dependent kinase inhibitors | MERCK SHARP & DOHME CORP. (US) | 2013-11-12 | — | — | US | disclosed |
| US-7807683-B2 | N-heteroaryl pyrazolopyrimidines as cyclin dependent kinase inhibitors | SCHERING CORPORATION (US) | 2010-10-05 | — | — | US | disclosed |
| US-20080050384-A1 | Novel pyrazolopyrimidines as cyclin dependent kinase inhibitors | SHERING CORPORATION AND PHARMACOPEIA, INC. | 2008-02-28 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080050384-A1 | Novel pyrazolopyrimidines as cyclin dependent kinase inhibitors | CDK2, CDK1, CDKN1A | GSK3B 695/4885CDK2 1/4885CCNA2 31/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.